secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0000059478-23-000160
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q1 revenue $6.96B (-11%); EPS $1.49 (-29%); core biz ex-COVID +10%; guidance raised
--------------------------------------------------------------------------------

- Revenue $6.96B, down 11% YoY; ex-COVID-19 antibodies up 10% on Mounjaro, Trulicity, Verzenio, Jardiance.
- Reported EPS $1.49, down 29%; non-GAAP EPS $1.62, down 38%; both include $0.10 acquired IPR&D.
- 2023 reported EPS guidance raised to $8.18-$8.38; non-GAAP to $8.65-$8.85 (up $0.30).
- New Products (Mounjaro, Jaypirca) contributed $573.6M; Growth Products rev $4.56B (+18%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947823000160/0000059478-23-000160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947823000160/lly-20230427.htm
  HTML page:      https://secwatch.observer/filing/0000059478-23-000160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer